• No results found

Response Evaluation Criteria in Solid Tumors

Evaluation of response from axitinib per response evaluation criteria in solid tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

Evaluation of response from axitinib per response evaluation criteria in solid tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

... Choi criteria (13% versus 60%, respectively) indicates that the use of Choi criteria to assess tumor response in patients with mRCC merits further research in a larger, prospective, and randomized ...

9

Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers

<p>Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers</p>

... only Response Evaluation Criteria in Solid Tumors, version ...Pathological evaluation has not been reported in these current clinical trials, and the effectiveness of anti-PD-1 ...

6

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment

... The evaluation of the therapeutic effects of chemother- apy for solid tumors based on the response evaluation criteria in solid tumors (RECIST) plays an important ...

9

Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug Eluting Beads

Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug Eluting Beads

... The response evaluation criteria in solid tumors (RECIST) are based on tumor shrinkage and are widely used in oncology to evaluate treatment response ...treatment response ...

9

All trans retinoic acid (ATRA) plus oxaliplatin plus 5 fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll

All trans retinoic acid (ATRA) plus oxaliplatin plus 5 fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial

... Tumor response will be evaluated in each subject every 4 weeks. Tumors will be evaluated by computed tomography (CT) or magnetic resonance imaging ...modified response evaluation ...

9

A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma

<p>A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma</p>

... tumor response at 3 months after TARE with 90 Y microspheres was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), no complete response was ...

10

PubMedCentral-PMC5616052.pdf

PubMedCentral-PMC5616052.pdf

... measurable response, per Response Evaluation Criteria in Solid ...these tumors can be subsequently surgically resected as part of routine veterinary care, pet dogs with sarcomas ...

9

The best objective response of target lesions and the incidence of treatment related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

The best objective response of target lesions and the incidence of treatment related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

... Terminology Criteria for Adverse Events version ...treatment response in accord- ance with the Response Evaluation Criteria in Solid Tumors (RECIST) version ...treatment ...

9

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

... imaging response by immune-related Response Evaluation Criteria in Solid Tumors, two had a partial response (including one with cortisol-producing ACC), seven had stable ...

9

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

... PET Response Criteria in Solid Tumors (iPERCIST), which was adapted from PERCIST; and the immune Response Evaluation Criteria in Solid Tumors ...time-point ...

10

Usefulness of Pseudocontinuous Arterial Spin Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period

Usefulness of Pseudocontinuous Arterial Spin Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period

... the Response Evaluation Criteria in Solid Tu- mors criteria by using their TV values in the pretreatment and early treatment periods as follows: patients whose percentage change of TV ...

7

Evaluation of therapeutic effect of tumor-targeted therapy

Evaluation of therapeutic effect of tumor-targeted therapy

... The response evaluation criteria in solid tumors, which are based on tumor size alone, are the most frequently used and effective criteria by which to evaluate the tumor ...

8

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

... exclusion criteria Twelve patients with solid tumors refractory to avail- able treatments were treated in this phase I clinical trial with ONCOS-102 (Table ...Inclusion criteria included age ...

18

Evaluation of tumor response to cytokine induced killer cells therapy in malignant solid tumors

Evaluation of tumor response to cytokine induced killer cells therapy in malignant solid tumors

... of response criteria were evaluated in a few large multinational studies on advanced melanoma re- ceiving ipilimumab, a fully human monoclonal antibody that blocks CTLA-4 ...distinct response ...

5

Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lung cancer in the eighth edition TNM classification

<p>Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lung cancer in the eighth edition TNM classification</p>

... part- solid and pure-solid tumors in lung adenocarcinoma, results consistent with fi ndings from the previous studies, 10,18,23 but inconsistent with those from ...part-solid tumors was ...

11

Early &alpha;-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

Early &alpha;-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

... radiological criteria for SD, for example mRECIST, have a relatively broad definition that includes a 20% increase to a 30% decrease from baseline enhanced tumor ...imaging-based response evaluation ...

9

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

... different tumors, and in dendritic cells, mac- rophages, and ...by tumors is driven by inflammation when cytokines such as interferon gamma are ...mechanism tumors utilize to escape immune ...that ...

10

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

... The analysis of drug resistance heterogeneity at RECIST- defined cancer progression was the next aim. Each me- tastasis was categorised as described into RL/SL/PL based on the diameter at progression compared to base- ...

9

Evaluation of tumor hypoxia and proliferation in canine spontaneous solid tumors

Evaluation of tumor hypoxia and proliferation in canine spontaneous solid tumors

... There is only limited support for the theory that radiation resistance due to tumor hypoxia can be effectively eliminated. Hypoxia-targeted therapy can be an excellent strategy to improve treatment outcome without ...

231

Mesenteric Fibromyoma Mimicking a Colon Tumor: A Diagnostic Dilemma

Mesenteric Fibromyoma Mimicking a Colon Tumor: A Diagnostic Dilemma

... Introduction: Solid primary tumors of mesenteric origin are quite rare among the intraabdominal soft tissue ...frequent tumors are Gastrointestinal Stromal Tumors (GIST) and smooth muscle ...

5

Show all 10000 documents...

Related subjects